Allergy drug and supplement face off in battle against cancer treatment bone pain

NCT ID NCT07300735

Recruiting now Symptom relief Sponsor: Alexandria University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two oral medications—diosmin-hesperidin (a flavonoid supplement) and loratadine (an allergy drug)—to prevent bone pain caused by G-CSF, a drug that boosts white blood cells in blood cancer patients. Researchers will compare each drug alone and in combination against a control in 88 adults. The goal is to find a safe, effective way to ease this common side effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Diosmin-Hesperidin and Loratadine
What this could lead to: If it works, this could point toward a simple, low-cost way to prevent a common side effect of cancer treatment.
What could go wrong: This is a small, early-stage study. The drugs may not reduce pain better than existing options, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm neutropenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE PAIN HEMATOLOGIC MALIGNANCY NEUTROPENIA

Contacts and locations

Locations

Alexandria University Hospitals
RECRUITING

Alexandria, 21532, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.